Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ONCOTRACK

Financiado

Cerrado

OncoTrack - Methods for systematic next generation oncology biomarker developmen...

OncoTrack - Methods for systematic next generation oncology biomarker development We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. De... ver más

31/12/2016

BAYER

31M€

Presupuesto del proyecto: 31M€

Líder del proyecto

Bayer Pharma AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 19 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2016-12-31 No tenemos la información de la convocatoria

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

19 Participantes

BAYER

Lider

FUNDACIO PRIVADA INSTITUT D'...

N.D. | Participante

Pfizer RD UK Limited

N.D. | Participante

MEDICAL UNIVERSITY OF GRAZ

N.D. | Participante

Proyectos interesantes

ONCOTRACK

Medical Technol...

Data Science

31M€ Cerrado

SIOMICS

Medical Technol...

Data Science

195K€ Cerrado

MultiCloneSeq

Medical Technol...

Data Science

150K€ Financiado

EQC2018-004733-P

Medical Technol...

Data Science

171K€ Cerrado

CNS2023-143848

Medical Technol...

Data Science

200K€ Cerrado

CANCEREVO

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 71 meses Fecha Inicio: 2011-01-01
Fecha Fin: 2016-12-31

Líder del proyecto

Bayer Pharma AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 31M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same patients. This will be complemented by the development and application of highly sensitive techniques to identify individual mutations, transcripts and proteins/protein complexes both in-situ in pathology slides as well as in patients’ blood or serum. The integration of these results will allow us to address the heterogeneity of the tumor samples, to deduce the genome/epigenome/transcriptome of the different cell types making up or originating from the tumor (e.g. circulating tumor cells, tumour stem cells or xenografts), to establish models able to predict suitable candidates for further biomarker development, and also to predict the effects and side effects of drugs in the treatment of genetically defined groups of patients. Available biomarkers, as well as biomarkers predicted from the work within the project will be validated in patient derived xenograft models and stem cell cultures, and ultimately transferred into a point of care (POC) diagnostic format. In parallel we will explore the use of the global genome and methylome information, e.g. derived from the analysis of free tumor DNA in the serum of the patient, as the ‘ultimate’ biomarker, to model the biology of the tumor (possibly even before any tumor has been localised), and as an independent route to predict clinically relevant parameters. Though sequencing/methylation analysis of the genome of the tumor through free DNA is currently still too costly for use as a routine diagnostic, this is likely to change over the period covered by the grant, due to the extremely rapid progress in the development of large scale sequencing techniques.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores